Saturday 17 October 2026
Export CTSO’s income statement to Excel — free account
Cytosorbents Corporation
CTSO Healthcare Medical Devices
Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 333.3%, free cash flow grew 64.9% and total debt rose 19.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.11
1.05
+34.31%
Follow CTSO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (336.17%) | (141.58%) | (96.39%) | (93.29%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 5 | 3 | 4 | |
| (42.38%) | (25.94%) | (17.91%) | (21.96%) | ||
ROIC |
(66.90%) | (60.60%) | (56.48%) | (53.58%) | |
Return on Tangible Assets |
1,634.83% | (132.17%) | (43.73%) | (52.96%) | |
Average Days of Receivables |
66.55 | 70.17 | 74.35 | 73.31 | |
Free Cash Flow per Share |
(3.00) | (3.34) | (4.11) | (3.23) | |
Free Cash Flow |
(9.42) | (10.49) | (12.79) | (10.14) | |
Capital Expenditures |
(0.27) | (0.41) | (0.41) | (0.25) | |
| Other line items | |||||
Cash ROIC |
(45.07%) | (43.76%) | (44.39%) | (32.58%) | |
Accounts Receivable Turnover |
5.12 | 5.02 | 4.98 | 5.26 | |
Accounts Payable Turnover |
3.92 | 3.34 | 3.41 | 4.11 | |
Inventory Turnover |
2.86 | 2.88 | 2.64 | 3.05 | |
Average Days of Payables |
69.15 | 105.99 | 99.05 | 100.36 | |
Days of Inventory on Hand |
127.32 | 151.64 | 182.33 | 132.34 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.27) | |
Research and Development Expense of Revenue |
12.46% | 11.95% | 13.72% | 15.84% | |
Selling, General and Administrative Expense of Revenue |
91.79% | 95.06% | 96.17% | 91.52% | |
Share Based Compensation of Revenue |
6.14% | 6.70% | 7.46% | 8.25% | |
Interest Coverage |
(4.15) | (4.86) | (5.65) | (5.53) | |
Operating CF/Net income |
0.50 | 0.85 | 1.51 | 0.96 | |
Depreciation/Fixed assets |
0.36 | 0.34 | 0.31 | 0.30 | |
Capex/Depreciation |
(0.11) | (0.16) | (0.17) | (0.10) | |
Revenue per Share |
11.85 | 11.86 | 11.91 | 11.79 | |
Operating CF per Share |
(2.91) | (3.21) | (3.98) | (3.15) | |
Capex per Share |
(0.09) | (0.13) | (0.13) | (0.08) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates